FOXO4-DRI
FOXO4-DRI (Senolytic Peptide)
FOXO4-DRI is a D-amino acid retro-inverso peptide designed to selectively eliminate senescent cells by disrupting the interaction between FOXO4 and p53 within those cells. It was developed as a senolytic agent following landmark research by Baar et al. (2017) demonstrating its ability to restore tissue homeostasis and physical function in aged and chemotherapy-damaged mice. It is primarily explored in research contexts for its potential to reduce the senescent cell burden associated with aging, fibrosis, and chemotherapy-induced side effects.
Mechanism of Action
Senescent cells survive in part because FOXO4 sequesters p53 within the nucleus, preventing p53-mediated apoptosis. FOXO4-DRI acts as a competitive inhibitor that disrupts this FOXO4-p53 interaction, freeing p53 to translocate to the mitochondria and initiate apoptosis selectively in senescent cells. Non-senescent cells are largely spared because they do not exhibit the same FOXO4-p53 co-localization, giving this peptide a degree of selectivity over conventional cytotoxic agents.
Evidence by Health Goal(12 goals)
Dosing Protocols
Administered subcutaneously or intraperitoneally in research settings; timing relative to meals not established as clinically relevant
Cycle: 3 weeks on, followed by a rest period of 1-3 months before reassessment
All published dosing data comes from preclinical mouse studies. Human dosing has not been established via clinical trials. The 1-5 mg/kg range is extrapolated from murine research (Baar et al. 2017). Self-administration in humans is entirely experimental and outside any validated safety framework.
Safety & Side Effects
FOXO4-DRI has demonstrated a favorable selectivity profile in preclinical rodent models, showing minimal toxicity to healthy tissue at effective senolytic doses. However, no human clinical trial safety data exists as of 2024, making its true safety profile in humans entirely unknown; use outside of supervised research settings carries substantial and undefined risk.
Possible Side Effects
- !Injection site reactions including erythema, induration, and local discomfort
- !Transient fatigue and malaise following injection (possibly related to inflammatory cytokine release from apoptotic senescent cells)
- !Flu-like symptoms in the days following dosing, consistent with senescent cell clearance and SASP resolution
- !Potential off-target apoptosis in rapidly dividing tissues at higher doses
- !Transient elevation of inflammatory markers during initial senolytic clearance phase
- !Unknown long-term immunological consequences of repeated senescent cell depletion in humans
Interactions
- -May potentiate cytotoxicity when combined with other senolytics such as dasatinib and quercetin, increasing risk of excessive senescent cell clearance
- -Concurrent use with chemotherapy agents may alter the senescent cell landscape in ways that are unpredictable and potentially harmful
- -Could theoretically interact with immunosuppressants by modifying the SASP-driven immune signaling environment
- -May amplify effects of anti-inflammatory drugs due to overlapping suppression of senescence-associated inflammatory pathways
Cost & Where to Buy
Available exclusively from research peptide vendors as a non-GMP research chemical. Cost varies significantly based on purity, synthesis quality, and vendor. A 3-week cycle at research doses for a 70kg individual requires approximately 200-1000mg total, placing monthly-equivalent cost in this range. Pharmaceutical-grade material does not exist commercially.
Search on Amazon